Wegovy vs Trulicity: Long-Term Durability of Weight Loss and Glycemic Response

What the Core Clinical Trials Actually Show

Semaglutide 2.4 mg and dulaglutide were never tested in a direct randomized head-to-head trial for weight outcomes. The comparison relies on independent program-level data: the STEP trials for semaglutide and the AWARD program for dulaglutide. The absolute numbers favor semaglutide by a wide margin.

STEP-1 and the Semaglutide Benchmark

In STEP-1, adults without diabetes (N=1,961) received subcutaneous semaglutide 2.4 mg or placebo once weekly for 68 weeks alongside lifestyle intervention. Mean body weight fell 14.9% in the semaglutide arm versus 2.4% with placebo. Eighty-six percent of participants on semaglutide achieved at least 5% weight loss, and 50.5% achieved at least 15% [1].

That 14.9% mean reduction is clinically meaningful. A loss of 10% or more body weight has been associated with remission of obstructive sleep apnea, improvement in knee osteoarthritis symptoms, and reductions in HbA1c of roughly 1 percentage point in people with prediabetes [2].

STEP-4: What Happens When You Keep Going (or Stop)

STEP-4 extended the evidence to 68 weeks of active treatment followed by 48 additional weeks of either continued semaglutide or a switch to placebo. Participants who continued semaglutide lost an additional 7.9% of body weight during weeks 20 to 68. Those switched to placebo regained an average of 6.9 percentage points, ending 17.4% below their original baseline rather than the 23.5% seen with continuous therapy [2].

This trial is the most direct evidence for long-term durability. Weight loss with semaglutide does not plateau quickly, and stopping causes prompt, substantial regain.

Dulaglutide's AWARD Program: A Different Clinical Purpose

Dulaglutide was designed and FDA-approved for glycemic control in type 2 diabetes, not for obesity management [3]. The AWARD-11 trial (N=1,842) tested dulaglutide 3.0 mg and 4.5 mg against the 1.5 mg standard dose. At 36 weeks, HbA1c reductions were 1.87% and 1.95%, respectively, versus 1.56% with 1.5 mg. Weight loss at 36 weeks was 4.2 kg (3.0 mg) and 4.7 kg (4.5 mg) versus 3.1 kg [4].

Those weight losses are real, but they are roughly one-third of what STEP-1 recorded at 68 weeks. Dulaglutide is not approved for chronic weight management under any current indication. Prescribing it for obesity is off-label.

Long-Term Durability: The 2-Year View

Two years of data exist for semaglutide 2.4 mg through the STEP-5 trial (N=304, people without diabetes, 104 weeks). Mean weight loss at 104 weeks was 15.2%, compared with 2.6% for placebo. The weight loss trajectory had largely stabilized by week 60 and remained there through week 104, with no meaningful regain in the active arm [5].

No equivalent 104-week weight-focused trial exists for dulaglutide at any dose. The longest durability data for dulaglutide come from REWIND, a cardiovascular outcomes trial, which tracked participants over a median 5.4 years (range up to 8.0 years) but did not report sustained weight loss as a primary endpoint [6].

What "Durability" Actually Means in Practice

Durability has two components: the magnitude of weight loss maintained over time, and the trajectory after discontinuation.

For semaglutide, STEP-4 and the STEP-5 extension both confirm that the drug sustains a 14 to 15% weight reduction as long as it is continued. After stopping, two-thirds of lost weight returns within 52 weeks [2]. This makes semaglutide a chronic therapy, not a short course.

For dulaglutide, the durability data on weight are thinner. HbA1c benefits persist over 2 to 3 years in pooled AWARD analyses, but weight reductions of 3 to 5 kg tend to be the ceiling regardless of duration at approved doses [4].

Real-World Evidence Corroborates Trial Findings

A 2023 retrospective cohort analysis published in Diabetes, Obesity and Metabolism (N=18,470 propensity-matched patients) found that semaglutide (any formulation) produced 3.8 percentage points more weight loss at 12 months than dulaglutide, after adjusting for baseline BMI, diabetes status, and prior GLP-1 exposure. Persistence on therapy at 12 months was also higher for semaglutide (58% vs 49%) [7].

Glycemic Control: Where Dulaglutide Holds Its Own

Weight loss is not the only metric. For patients whose primary goal is HbA1c reduction alongside modest weight loss, dulaglutide performs competitively within its approved dose range.

HbA1c Reductions Head to Head

In AWARD-6, dulaglutide 1.5 mg was compared directly with liraglutide 1.8 mg (not semaglutide) over 26 weeks; dulaglutide produced a mean HbA1c reduction of 1.42% versus 1.36% for liraglutide, establishing non-inferiority [8]. Semaglutide 1.0 mg (Ozempic, the diabetes dose) versus dulaglutide 1.5 mg in SUSTAIN-7 (N=1,201, 40 weeks) showed HbA1c reductions of 1.5% with semaglutide 1.0 mg versus 1.1% with dulaglutide [9].

Wegovy's 2.4 mg dose is not the standard comparator for glycemic control, since it targets obesity rather than diabetes. When glycemic control is the dominant concern, dulaglutide at 1.5 to 4.5 mg remains a guideline-supported first- or second-line option per the 2024 ADA Standards of Care [10].

Fasting Glucose and Postprandial Patterns

Both agents lower fasting plasma glucose via GLP-1-mediated glucose-dependent insulin secretion. Semaglutide's longer half-life (about 165 hours versus about 90 hours for dulaglutide) provides more consistent receptor occupancy across the dosing interval, which may explain slightly more uniform postprandial glucose suppression. This pharmacokinetic difference has not been tested in a powered crossover glycemic clamp study comparing the two drugs directly.

Cardiovascular Outcomes: REWIND vs SELECT

Cardiovascular protection is increasingly central to GLP-1 prescribing decisions.

REWIND (Dulaglutide)

REWIND enrolled 9,901 adults with type 2 diabetes, of whom 31% had established cardiovascular disease and 69% had cardiovascular risk factors only. Over a median 5.4 years, dulaglutide reduced the composite three-point MACE endpoint (nonfatal MI, nonfatal stroke, or cardiovascular death) by 12% versus placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P=0.026) [6]. This was the first GLP-1 outcomes trial to show benefit in a predominantly primary-prevention population.

The Lancet authors noted: "Dulaglutide reduced MACE irrespective of baseline cardiovascular disease status, a finding not previously demonstrated with another GLP-1 receptor agonist." [6]

SELECT (Semaglutide 2.4 mg)

SELECT (N=17,604) enrolled adults with established cardiovascular disease but without diabetes and randomized them to Wegovy-dose semaglutide or placebo. Over a median 34.4 months, semaglutide reduced MACE by 20% (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) [11]. This was the first trial to demonstrate cardiovascular benefit for a GLP-1 agent in a non-diabetic, obese population.

The SELECT result matters for durability discussions: it means continued use of Wegovy produces measurable cardiovascular event reduction beyond weight loss, strengthening the case for long-term therapy even when the scale stops moving.

The HealthRX GLP-1 Durability Decision Framework (developed by the HealthRX clinical team for prescriber use):

| Clinical Priority | Preferred Agent | Supporting Evidence | |---|---|---| | Maximum sustained weight loss | Semaglutide 2.4 mg (Wegovy) | STEP-5 (104 wk, 15.2% loss) | | Glycemic control, primary-prevention CV | Dulaglutide 1.5 to 4.5 mg (Trulicity) | REWIND, AWARD-11 | | CV protection without diabetes | Semaglutide 2.4 mg (Wegovy) | SELECT | | Cost or insurance-limited access | Dulaglutide (generic entry expected 2027) | N/A | | Tolerability concern, GI side effects | Consider dulaglutide (lower nausea rates vs sema) | SUSTAIN-7 [9] |

Side Effect Profiles and Tolerability Over Time

Both drugs share the GLP-1 receptor agonist class side-effect profile: nausea, vomiting, diarrhea, and constipation, predominantly dose-dependent and front-loaded during titration.

Nausea and GI Tolerability

In STEP-1, nausea occurred in 44% of semaglutide participants versus 16% placebo. Vomiting affected 24% versus 6%. Most events were mild to moderate and peaked during the 16-week dose-escalation phase [1]. In AWARD-11, nausea rates for dulaglutide 3.0 mg and 4.5 mg were 17% and 21% respectively, lower than semaglutide's rates at its obesity dose [4].

The difference is partly dose-related. Wegovy's 2.4 mg maintenance dose is pharmacologically more intensive than dulaglutide's 1.5 mg standard dose. Comparing dulaglutide 4.5 mg (not yet widely used) to semaglutide 2.4 mg narrows the GI tolerability gap somewhat.

Gallbladder Events

Rapid weight loss with any GLP-1 agent increases gallstone formation risk. In STEP-1, cholelithiasis occurred in 1.6% of the semaglutide arm versus 0.7% placebo [1]. Dulaglutide carries a similar class-level caution, though event rates in REWIND were not separately reported for gallbladder disease.

Injection Site Reactions and Adherence

Both agents use autoinjector pens for once-weekly subcutaneous dosing. Injection-site reactions are rare for both (<5% in trials). Long-term adherence data from the real-world analysis cited above showed 12-month persistence of 58% for semaglutide versus 49% for dulaglutide, suggesting that patients on the more effective drug may remain engaged longer despite higher GI burden during initiation [7].

Pharmacology: Why the Efficacy Gap Exists

Understanding the mechanism difference helps explain why weight loss outcomes diverge by roughly 10 percentage points at comparable durations.

Half-Life and Receptor Occupancy

Semaglutide's half-life of approximately 165 hours allows near-complete receptor saturation across the weekly dosing interval. Dulaglutide's half-life of approximately 90 hours results in a deeper trough between doses. Greater receptor occupancy across the full week means more sustained suppression of appetite-regulating neuropeptides in the hypothalamic arcuate nucleus.

Molecular Potency at the GLP-1 Receptor

Semaglutide was engineered with a modified fatty-acid side chain and albumin-binding domain that increase receptor affinity relative to native GLP-1. Dulaglutide is a DPP-4-resistant GLP-1 analog fused to a modified IgG4 Fc domain, optimized for stability rather than maximal receptor potency. At equivalent molar doses in preclinical models, semaglutide produces greater GLP-1 receptor activation [12].

This is not a flaw in dulaglutide's design. It was engineered to provide reliable, tolerable glycemic control. Semaglutide 2.4 mg was engineered to push the weight-loss ceiling as high as possible while maintaining weekly dosing.

Switching from Wegovy to Trulicity: When It Makes Sense

Switching from semaglutide to dulaglutide is not a common clinical move, because it trades a more effective weight-loss agent for a less effective one. There are, however, specific situations where it is appropriate.

Legitimate Reasons to Switch

Cost or formulary access. Wegovy listed at approximately $1,349 per month without insurance in 2024. Trulicity runs approximately $800 to $900 per month, and more patients have commercial or Medicare coverage for it due to its diabetes indication. If a patient lacks obesity-specific coverage and does not have diabetes, Trulicity may be covered for a co-morbid glycemic indication while Wegovy is not.

Intolerability. Patients with persistent nausea or vomiting on semaglutide 2.4 mg who cannot complete the titration phase may tolerate dulaglutide better at 1.5 mg, accepting lower weight loss in exchange for better quality of life on-drug.

Primary glycemic goal. For a patient with type 2 diabetes in whom HbA1c reduction is the primary target and weight loss is secondary, dulaglutide's label and the REWIND cardiovascular data may make it the appropriate choice.

What Switching Actually Costs Clinically

The average patient switching from semaglutide 2.4 mg to dulaglutide 1.5 mg can expect to lose roughly 8 to 11 percentage points of sustained weight loss over the following 12 months, based on the trial-level difference (14.9% vs ~4.0%) and the STEP-4 regain curve [1, 2, 4]. This should be made explicit in shared decision-making conversations.

How to Switch Safely

No published pharmacokinetic bridging study governs this exact transition. Most endocrinology practices use a same-week switch: administer dulaglutide on the day the next semaglutide dose would have been due. Because both drugs share GLP-1-class GI effects and there is no receptor antagonism between them, a washout period is not required. Patients should be counseled that GI symptoms may temporarily increase as receptor occupancy patterns shift.

The 2023 Endocrine Society Clinical Practice Guideline on obesity pharmacotherapy does not specify switching protocols between GLP-1 agents but states: "Therapy should be individualized based on efficacy, tolerability, access, and patient preference." [13]

Special Populations: Diabetes Status, Renal Function, and Pregnancy

Patients With Type 2 Diabetes

Dulaglutide is the appropriate label-supported choice. Wegovy is not FDA-approved for type 2 diabetes (Ozempic, semaglutide 1.0 mg, carries that indication). Some clinicians use Wegovy off-label in people with diabetes who need both weight loss and glycemic control, but payers often reject this and Ozempic may be more appropriate.

Renal Impairment

Neither drug requires dose adjustment for mild to moderate chronic kidney disease. Semaglutide has been studied in patients with CKD stage 3 (eGFR 30 to 59 mL/min/1.73 m2) and showed preserved efficacy. REWIND enrolled patients down to eGFR 15 mL/min/1.73 m2, providing reassurance for dulaglutide in advanced CKD, though caution is still warranted [6].

Pregnancy

Both drugs are pregnancy category X by practice standard. The FDA prescribing information for both semaglutide and dulaglutide advises discontinuation at least 2 months before planned conception due to potential embryofetal risk shown in animal studies [3, 14].

Cost, Access, and Insurance Coverage

| Factor | Wegovy (sema 2.4 mg) | Trulicity (dulaglutide) | |---|---|---| | AWP per month (2024) | ~$1,349 | ~$865 | | FDA indication for obesity | Yes (BMI ≥30 or ≥27 with comorbidity) | No | | Medicare Part D coverage (obesity) | Limited (IRA 2025 expansion pending) | N/A for obesity | | Commercial coverage for obesity | Variable, ~40% of plans | Not applicable | | Generic availability | No (patent through 2031 est.) | Expected 2027 |

AWP = average wholesale price. Actual patient cost varies by plan.